• +1-646-491-9876
    • +91-20-67278686

    Search

    Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

    Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

    • Report Code ID: RW0001492626
    • Category Pharmaceuticals
    • No. of Pages 477
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.

    The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment options include drugs not already used during past treatment and conditioning therapy followed by transplantation.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Refractory Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 34, 39, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 6 and 1 molecules, respectively.Refractory Acute Myeloid Leukemia.

    Refractory Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia (Oncology).
    - The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Refractory Acute Myeloid Leukemia Overview 7
    Therapeutics Development 8
    Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies 10
    Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 14
    Refractory Acute Myeloid Leukemia - Pipeline Products Glance 15
    Refractory Acute Myeloid Leukemia - Products under Development by Companies 18
    Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 24
    Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 25
    Refractory Acute Myeloid Leukemia - Therapeutics Assessment 85
    Drug Profiles 107
    Refractory Acute Myeloid Leukemia - Dormant Projects 448
    Refractory Acute Myeloid Leukemia - Discontinued Products 451
    Refractory Acute Myeloid Leukemia - Product Development Milestones 452
    Appendix 465

    List of Tables

    Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19
    Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016 20
    Number of Products under Development by Companies, H2 2016 21
    Number of Products under Development by Companies, H2 2016 (Contd..1) 22
    Number of Products under Development by Companies, H2 2016 (Contd..2) 23
    Number of Products under Development by Companies, H2 2016 (Contd..3) 24
    Number of Products under Investigation by Universities/Institutes, H2 2016 25
    Comparative Analysis by Late Stage Development, H2 2016 26
    Comparative Analysis by Clinical Stage Development, H2 2016 27
    Comparative Analysis by Early Stage Development, H2 2016 28
    Products under Development by Companies, H2 2016 29
    Products under Development by Companies, H2 2016 (Contd..1) 30
    Products under Development by Companies, H2 2016 (Contd..2) 31
    Products under Development by Companies, H2 2016 (Contd..3) 32
    Products under Development by Companies, H2 2016 (Contd..4) 33
    Products under Development by Companies, H2 2016 (Contd..5) 34
    Products under Investigation by Universities/Institutes, H2 2016 35
    Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016 36
    Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016 37
    Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 38
    Refractory Acute Myeloid Leukemia - Pipeline by ADC Therapeutics Sarl, H2 2016 39
    Refractory Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 40
    Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals Inc, H2 2016 41
    Refractory Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics Inc, H2 2016 42
    Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc, H2 2016 43
    Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals Inc, H2 2016 44
    Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc, H2 2016 45
    Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc, H2 2016 46
    Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016 47
    Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 48
    Refractory Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 49
    Refractory Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 50
    Refractory Acute Myeloid Leukemia - Pipeline by BioLineRx Ltd, H2 2016 51
    Refractory Acute Myeloid Leukemia - Pipeline by BioSight Ltd, H2 2016 52
    Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 53
    Refractory Acute Myeloid Leukemia - Pipeline by Boston Biomedical Inc, H2 2016 54
    Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016 55
    Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences Inc, H2 2016 56
    Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corp, H2 2016 57
    Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 58
    Refractory Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 59
    Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp, H2 2016 60
    Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 61
    Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co Ltd, H2 2016 62
    Refractory Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016 63
    Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme Inc, H2 2016 64
    Refractory Acute Myeloid Leukemia - Pipeline by Exelixis Inc, H2 2016 65
    Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 66
    Refractory Acute Myeloid Leukemia - Pipeline by Fate Therapeutics Inc, H2 2016 67
    Refractory Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016 68
    Refractory Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016 69
    Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corp, H2 2016 70
    Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016 71
    Refractory Acute Myeloid Leukemia - Pipeline by GlycoMimetics Inc, H2 2016 72
    Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics Inc, H2 2016 73
    Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corp, H2 2016 74
    Refractory Acute Myeloid Leukemia - Pipeline by Io Therapeutics Inc, H2 2016 75
    Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corp, H2 2016 76
    Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics Inc, H2 2016 77
    Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 78
    Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics Inc, H2 2016 79
    Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co Inc, H2 2016 80
    Refractory Acute Myeloid Leukemia - Pipeline by Merck KGaA, H2 2016 81
    Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 82
    Refractory Acute Myeloid Leukemia - Pipeline by NantKwest Inc, H2 2016 83
    Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016 84
    Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 85
    Refractory Acute Myeloid Leukemia - Pipeline by Pfizer Inc, H2 2016 86
    Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar SA, H2 2016 87
    Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 88
    Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics Inc, H2 2016 89
    Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 90
    Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2016 91
    Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 92
    Refractory Acute Myeloid Leukemia - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 93
    Refractory Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 94
    Refractory Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology Inc, H2 2016 95
    Assessment by Monotherapy Products, H2 2016 96
    Assessment by Combination Products, H2 2016 97
    Number of Products by Stage and Target, H2 2016 99
    Number of Products by Stage and Mechanism of Action, H2 2016 107
    Number of Products by Stage and Route of Administration, H2 2016 115
    Number of Products by Stage and Molecule Type, H2 2016 117
    Refractory Acute Myeloid Leukemia - Dormant Projects, H2 2016 459
    Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016 460
    Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..2), H2 2016 461
    Refractory Acute Myeloid Leukemia - Discontinued Products, H2 2016 462

    List of Figures

    Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19
    Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016 20
    Number of Products under Development by Companies, H2 2016 21
    Number of Products under Investigation by Universities/Institutes, H2 2016 25
    Comparative Analysis by Late Stage Development, H2 2016 26
    Comparative Analysis by Clinical Stage Development, H2 2016 27
    Comparative Analysis by Early Stage Products, H2 2016 28
    Assessment by Monotherapy Products, H2 2016 96
    Number of Products by Top 10 Targets, H2 2016 98
    Number of Products by Stage and Top 10 Targets, H2 2016 98
    Number of Products by Top 10 Mechanism of Actions, H2 2016 106
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 106
    Number of Products by Routes of Administration, H2 2016 114
    Number of Products by Stage and Routes of Administration, H2 2016 114
    Number of Products by Molecule Types, H2 2016 116
    Number of Products by Stage and Molecule Types, H2 2016 116
    4SC AG
    AbbVie Inc
    Actinium Pharmaceuticals Inc
    ADC Therapeutics Sarl
    Aeglea BioTherapeutics Inc
    Agios Pharmaceuticals Inc
    Aileron Therapeutics Inc
    Amgen Inc
    Arog Pharmaceuticals Inc
    Array BioPharma Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Bellicum Pharmaceuticals Inc
    Bio-Cancer Treatment International Ltd
    BioLineRx Ltd
    BioSight Ltd
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Calithera Biosciences Inc
    Celgene Corp
    Cornerstone Pharmaceuticals Inc
    CSPC Pharmaceutical Group Limited
    CTI BioPharma Corp
    Daiichi Sankyo Company Ltd
    Eisai Co Ltd
    Eli Lilly and Company
    EpiZyme Inc
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    Fate Therapeutics Inc
    FLX Bio, Inc.
    FORMA Therapeutics Inc
    Fujifilm Corp
    GlaxoSmithKline Plc
    GlycoMimetics Inc
    Igenica Biotherapeutics Inc
    Incyte Corp
    Io Therapeutics Inc
    JW Pharmaceutical Corp
    Karyopharm Therapeutics Inc
    Kyowa Hakko Kirin Co Ltd
    MacroGenics Inc
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    NantKwest Inc
    Novartis AG
    Oxford BioTherapeutics Ltd
    Pfizer Inc
    Pharma Mar SA
    Polaris Pharmaceuticals Inc
    Seattle Genetics Inc
    Sunesis Pharmaceuticals Inc
    TaiGen Biotechnology Co Ltd
    Tolero Pharmaceuticals Inc
    Tragara Pharmaceuticals Inc
    VioQuest Pharmaceuticals Inc
    ZIOPHARM Oncology Inc

    Request for Sample

    Report Url https://www.reportsweb.com//refractory-acute-myeloid-leukemia-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//refractory-acute-myeloid-leukemia-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//refractory-acute-myeloid-leukemia-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments